Anti-PD-1 therapy could improve their responsiveness and tumor control even in the absence of T cell cells, indicating that, in addition to T cells, other immune cells, such as NK cells, could also mediate the effect of PD-1/PD-L1 blockade immunotherapy (3, 4). The gene discussed is PDCD1; the disease is neoplasm.